Lataa...
AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas
BACKGROUND: AXL is a well-characterized, protumorigenic receptor tyrosine kinase that is highly expressed and activated in numerous human carcinomas and sarcomas, including aggressive subtypes of liposarcoma. However, the role of AXL in the pathogenesis of well-differentiated (WDLPS), dedifferentiat...
Tallennettuna:
| Julkaisussa: | BMC Cancer |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4647521/ https://ncbi.nlm.nih.gov/pubmed/26573603 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1916-3 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|